Using pharmacological inhibition of RIOK1 analog sensitive versions, we found that MTAP-proficient and deficient cells depend equally on RIOK1 kinase activity, arguing against the notion that the inhibition of RIOK1 kinase activity can be therapeutically exploited for selectively targeting MTAP-deleted cancers. The gene discussed is MTAP; the disease is cancer.